There are 3 medications that are currently approved for treatment in acute attacks in HAE that include a plasma-derived C1 INH for intravenous administration and bradykinin antagonist and inhibitors icatibant and ecallantide via subcutaneous administration [14, 25, 26]. This evidence concerns the gene SERPING1 and hereditary angioedema.